The United States Centers for Disease Control and Prevention and the US Food and Drug Administration on Tuesday recommended suspending the use of the Johnson & Johnson COVID-19 vaccine.
The development comes after six recipients of the vaccine — all women– developed a “severe type of blood clot.”
A joint statement by the agencies, said they are “reviewing data involving 6 reported U.S. cases of a rare & severe type of blood clot in individuals after receiving the vaccine. Right now, these adverse events appear to be extremely rare.”
“Treatment of this specific type of blood clot is different from the treatment that might typically be administered,” the statement reads.
“CDC will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further review these cases and assess their potential significance. FDA will review that analysis as it also investigates these cases.
“Until that process is complete, we are recommending this pause. This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot.”
Meanwhile, the World Health Organisation (WHO) had on March 12 listed the Johnson & Johnson COVID-19 vaccine for emergency use in all countries.
Also in another news WHO’s chief Tedros Adhanom Ghebreyesus said the pandemic is “a long way from over,” however, it can be brought under control in months with proven public health measures.